Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

578
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
578
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of lighted catheter phototherapy in endoscopic treatment of urethral strictures: a rabbit pilot study.

International urology and nephrology·2026
Same author

The Kidneys Went Nuts: Oxalate Nephropathy From Excessive Cashew Nut Consumption.

Kidney medicine·2026
Same author

Serine protease HTRA1 is a common autoantigen in membranous nephropathy in patients of 80 years and older.

Kidney international·2026
Same author

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.

The oncologist·2026
Same author

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Proteomic Profiling of Complement Components in Glomerular Disease.

Laboratory investigation; a journal of technical methods and pathology·2026

Related Experiment Video

Updated: Mar 12, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.0K

Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.

Raju Chelluri1, Tiffany Caza2, Mark R Woodford1

  • 1Department of Urology, State University of New York, Upstate Medical University, Syracuse, NY, U.S.A.

Anticancer Research
|November 1, 2016
PubMed
Summary

Valproic acid (VPA) significantly reduces prostate cancer (PCa) cell proliferation in laboratory studies. This compound also impacts genes involved in blood vessel growth (angiogenesis) and cell cycle control, suggesting a potential therapeutic avenue for PCa.

Keywords:
Prostatic neoplasmshistone deacetylase inhibitorsneovascularizationpathologicthrombospondin 1valproic acid

More Related Videos

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Experiment Videos

Last Updated: Mar 12, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.0K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Prostate cancer (PCa) affects a minority of men, but progression necessitates improved therapeutic strategies.
  • Investigating novel agents to prevent PCa progression is crucial for altering treatment paradigms.

Purpose of the Study:

  • To determine the effect of valproic acid (VPA) on prostate cancer (PCa) cell proliferation.
  • To assess VPA's impact on angiogenesis and PCa-specific signaling pathways.

Main Methods:

  • LNCaP cells were treated with VPA for 72 hours to measure proliferation.
  • Gene expression analysis using RT-profiler arrays, followed by validation with real-time PCR and Western blot.

Main Results:

  • VPA demonstrated a dose-dependent reduction in PCa cell proliferation.
  • Gene expression analysis indicated VPA affects angiogenesis modulators and cell-cycle control transcripts.
  • Strong correlation observed between validated gene and protein expression levels.

Conclusions:

  • Valproic acid (VPA) inhibits cellular proliferation in prostate cancer (PCa) cells in vitro.
  • VPA influences gene expression, suggesting anti-angiogenic effects and a decrease in proliferation-related genes.